Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -334.15% is 26% below its 2-year average of -265.11%, around the middle of its 2-year range (-1020.46%–-4.14%).
34.59% above its 12-month average of -510.85%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -392.64%.
EBITDA MARGIN
-334.15%
EBITDA MARGIN AVG TTM
-510.85%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+34.59%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$8.42M
EBITDA Margin
-65.39%
TTM Avg
-49.20%
3Y Avg
-36.51%
5Y Avg
-25.14%
Market Cap
$8.25M
EBITDA Margin
-194787.38%
TTM Avg
-191929.49%
3Y Avg
-133856.30%
5Y Avg
-96317.48%
Market Cap
$8.05M
EBITDA Margin
-33055.56%
TTM Avg
-18473.68%
3Y Avg
-9547.23%
5Y Avg
-12604.39%
Market Cap
$8.05M
EBITDA Margin
-951.52%
TTM Avg
-1801.56%
3Y Avg
-1801.56%
5Y Avg
-1801.56%
Market Cap
$8.00M
EBITDA Margin
-144973.96%
TTM Avg
-73136.05%
3Y Avg
-36678.29%
5Y Avg
-29395.87%
Market Cap
$9.36M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DataMEDS AI, Inc. (MEDS) | $8.53M | -334.15% | -510.85% | N/A | N/A |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.42M | -65.39% | -49.20% | -36.51% | -25.14% |
| HeartSciences Inc. (HSCS)vs › | $8.25M | -194787.38% | -191929.49% | -133856.30% | -96317.48% |
| GT Biopharma, Inc. (GTBP)vs › | $8.05M | -33055.56% | -18473.68% | -9547.23% | -12604.39% |
| Aprea Therapeutics, Inc. (APRE)vs › | $8.05M | -951.52% | -1801.56% | -1801.56% | -1801.56% |
| ENDRA Life Sciences Inc. (NDRA)vs › | $8.00M | -144973.96% | -73136.05% | -36678.29% | -29395.87% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.96M | N/A | N/A | N/A | N/A |
| Jasper Therapeutics, Inc. (JSPR)vs › | $9.21M | N/A | N/A | N/A | N/A |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $9.36M | N/A | N/A | N/A | N/A |
| SeaStar Medical Holding Corporation (ICU)vs › | $9.37M | -985.17% | -7100.73% | -7100.73% | -7100.73% |
Gross Margin
-41.3%
EBITDA Margin
-334.1%
Operating Margin
-347.9%
Net Margin
-1100.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -392.64% |
| 2026-03-31 | -362.84% |
| 2025-12-31 | -717.99% |
| 2025-09-30 | -1020.46% |
| 2025-06-30 | -60.30% |
| 2025-03-31 | -281.18% |
| 2024-12-31 | -24.98% |
| 2024-09-30 | -22.74% |
| 2024-06-30 | -4.14% |
| 2024-03-31 | -12.82% |
| 2023-12-31 | -16.07% |
